



## Samarium Sm 153 Lexidronam Pentasodium

Revised: August 17, 2020.

CASRN: 160369-78-8

### Drug Levels and Effects

#### Summary of Use during Lactation

Information in this record refers to the use of samarium Sm 153 lexidronam pentasodium as a therapeutic agent. No information is available on the use of samarium Sm 153 lexidronam pentasodium during breastfeeding. Most conditions treated with samarium Sm 153 would not occur in mothers wishing to nurse. However, the manufacturer recommends not administering the drug in women who wish to continue breastfeeding. Because of the relatively long half-life of samarium 153, the standard waiting period of 10 half-lives would be close to 3 weeks which might be impractical for resuming breastfeeding. The manufacturer and expert opinion recommend discontinuing breastfeeding if the agent is administered.[1]

Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at background levels they may safely resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[2]

#### Drug Levels

Samarium Sm 153 emits both medium-energy beta particles and a gamma photon, and has a physical half-life of 1.93 days.

#### Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

#### Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

---

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

## References

1. Bodei L, Lam M, Chiesa C, et al. EANM procedure guideline for treatment of refractory metastatic bone pain. *Eur J Nucl Med Mol Imaging*. 2008;35:1934–40. PubMed PMID: 18649080.
2. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: Mechanisms, findings, and radiation dosimetry. *J Nucl Med*. 2000;41:863–73. PubMed PMID: 10809203.

## Substance Identification

### Substance Name

Samarium Sm 153 Lexidronam Pentasodium

### CAS Registry Number

160369-78-8

### Drug Class

Breast Feeding

Lactation

Radiopharmaceuticals

Samarium Radioisotopes